Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03256045 · OUTCOME

Multiple Myeloma Cells In-vitro Drug Sensitivity to Carfilzomib, by Subject

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2022-05-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
nM
Interval / dispersion
Not reported
Time frame
At baseline

What was measured

Multiple myeloma cells are added to assay with carfilzomib. Cell viability and IC50 is determined. IC50 is the inhibitory concentration that kills 50% of cells.

Groups in this outcome

Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone

Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone9

Reported measurements

Subject MM-82
Values in nM · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone17.5Not reportedNot reportedNot reportedNot reported
Subject MM-91
Values in nM · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone0.479Not reportedNot reportedNot reportedNot reported
Subject MM-92
Values in nM · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone0.03Not reportedNot reportedNot reportedNot reported
Subject MM-95
Values in nM · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone0.269Not reportedNot reportedNot reportedNot reported
Subject MM-96
Values in nM · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone0.0048Not reportedNot reportedNot reportedNot reported
Subject MM-98
Values in nM · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone0.159Not reportedNot reportedNot reportedNot reported
Subject MM-99
Values in nM · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone0.159Not reportedNot reportedNot reportedNot reported
Subject MM-109
Values in nM · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone0.108Not reportedNot reportedNot reportedNot reported
Subject MM-111
Values in nM · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone0.0152Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        17.5
    title
    Subject MM-82
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0.479
    title
    Subject MM-91
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0.03
    title
    Subject MM-92
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        0.269
    title
    Subject MM-95
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        0.0048
    title
    Subject MM-96
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        0.159
    title
    Subject MM-98
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        0.159
    title
    Subject MM-99
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        0.108
    title
    Subject MM-109
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        0.0152
    title
    Subject MM-111
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    units
    Participants
description
Multiple myeloma cells are added to assay with carfilzomib. Cell viability and IC50 is determined. IC50 is the inhibitory concentration that kills 50% of cells.
groups
  1. description
    Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
param Type
NUMBER
reporting Status
POSTED
time Frame
At baseline
title
Multiple Myeloma Cells In-vitro Drug Sensitivity to Carfilzomib, by Subject
type
PRIMARY
unit Of Measure
nM

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice